OTCMKTS:ADDXF Addex Therapeutics (ADDXF) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free ADDXF Stock Alerts $0.99 0.00 (0.00%) (As of 02/3/2023) Add Compare Share Share Today's Range$0.99▼$0.9950-Day Range$0.99▼$0.9952-Week Range$0.99▼$0.99VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Addex Therapeutics alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now. About Addex Therapeutics Stock (OTCMKTS:ADDXF)Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Read More ADDXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADDXF Stock News HeadlinesMarch 24, 2024 | markets.businessinsider.comAddex Therapeutics earnings: here's what to expectMarch 22, 2024 | investing.comAddex Therapeutics Ltd (ADXN)April 25, 2024 | Chaikin Analytics (Ad)“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.January 25, 2024 | morningstar.comADRs Close Higher; Addex Therapeutics Climbs 21%November 28, 2023 | markets.businessinsider.comAddex Therapeutics is about to announce its earnings — here's what to expectOctober 6, 2023 | benzinga.comAddex Announces Plan to Implement ADS Ratio ChangeSeptember 20, 2023 | markets.businessinsider.comAddex mGlu2 NAM Cognition Program Receives €4 Million GrantSeptember 4, 2023 | tmcnet.comAddex's Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in BrainApril 25, 2024 | Chaikin Analytics (Ad)“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.July 24, 2023 | benzinga.comAddex mGlu2PAM Demonstrates Potential in Substance Use DisorderMay 12, 2023 | benzinga.comAddex Therapeutics Q1 EPS $(0.04) Up From $(0.97) YoY, Sales $542.43K Up From $264.20K YoYMay 10, 2023 | benzinga.comAddex Announces ADX71149 Phase 2 Epilepsy Clinical Study's Independent Interim Review Committee Recommends Continuing StudyApril 5, 2023 | finanznachrichten.deAddex Therapeutics: Addex Completes $5.0 Million Equity FinancingApril 5, 2023 | benzinga.comAddex Completes $5.0 Million Equity FinancingApril 4, 2023 | tmcnet.comAddex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson's DiseaseMarch 30, 2023 | markets.businessinsider.comAddex Therapeutics FY22 Loss Widens, Income DownJune 17, 2022 | benzinga.comAddex Stops Parkinson's-Associated Dyskinesia Trial - Read Here WhySee More Headlines Receive ADDXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ADDXF CUSIPN/A CIKN/A Webwww.addextherapeutics.com Phone41 22 884 1555FaxN/AEmployees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.25 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Timothy Mark Dyer (Age 54)Co-Founder, CEO & Director Dr. Roger G. Mills M.D. (Age 65)Chief Medical Officer & Director Mr. Lénaic Teyssédou (Age 36)Head of Fin. Dr. Jean-Philippe Rocher Ph.D. (Age 63)Head of Discovery - Chemistry Dr. Robert Lutjens (Age 54)Head of Discovery - Biology Dr. Mikhail Kalinichev Ph.D. (Age 54)Head of Translational Science Dr. Werner Henrichi Ph.D. (Age 79)Consultant More ExecutivesKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAffymaxOTCMKTS:AFFYAlseres PharmaceuticalsOTCMKTS:ALSEAmerican Bio MedicaOTCMKTS:ABMCView All Competitors ADDXF Stock Analysis - Frequently Asked Questions How have ADDXF shares performed in 2024? Addex Therapeutics' stock was trading at $0.99 at the start of the year. Since then, ADDXF stock has increased by 0.0% and is now trading at $0.99. View the best growth stocks for 2024 here. How do I buy shares of Addex Therapeutics? Shares of ADDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ADDXF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmith“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
